DLL1 (Delta-Like 1) encodes a transmembrane ligand of the Delta/Serrate/Lag-2 (DSL) family that activates Notch receptors through cell-cell contact. DLL1 is the principal Notch ligand in the adult brain, where it critically regulates neural stem cell maintenance, adult neurogenesis, synaptic plasticity, and neuronal survival. Dysregulation of DLL1-Notch signaling has been strongly implicated in Alzheimer's disease pathogenesis, where amyloid-beta disrupts Notch-dependent processes, and in Parkinson's disease, where impaired Notch signaling contributes to dopaminergic neuron vulnerability.
| Property |
Value |
| Symbol |
DLL1 |
| Full Name |
Delta-Like 1 |
| Chromosomal Location |
6q27 |
| NCBI Gene ID |
28514 |
| OMIM ID |
604552 |
| Ensembl ID |
ENSG00000198719 |
| UniProt ID |
O00548 |
| Protein Length |
723 amino acids |
| Molecular Weight |
~82 kDa |
| Expression |
Brain (hippocampus, cortex, SVZ), neural stem cells, neurons, astrocytes |
| Associated Diseases |
AD, PD, neurodevelopmental disorders, cancer |
¶ Gene Structure and Expression
The DLL1 gene spans approximately 20 kb on chromosome 6q27 and contains 24 exons. The gene is regulated by multiple promoters and enhancers that control its spatial and temporal expression pattern.
DLL1 is expressed in a dynamic pattern during development and in the adult brain:
- Neural stem cells: High expression in the subventricular zone (SVZ) and hippocampal subgranular zone (SGZ), where it maintains stem cell identity through lateral inhibition
- Postmitotic neurons: Expressed in hippocampal and cortical neurons, where it modulates synaptic function
- Astrocytes: Lower expression in astrocytes, suggesting potential paracrine Notch ligand activity
- Oligodendrocyte precursors: Expression during differentiation suggests a role in myelination
Expression is activity-dependent: synaptic activity upregulates DLL1 in excitatory neurons, providing a feedback mechanism linking circuit activity to Notch-mediated gene expression.
¶ Domain Architecture
The DLL1 protein contains several critical structural elements:
- N-terminal DSL domain: Conserved region essential for binding to Notch receptors
- EGF-like repeats: Eight EGF-like repeats mediating receptor-ligand interaction
- MNNL domain: Module at the N-terminus involved in protein interactions
- Transmembrane helix: Single pass transmembrane domain anchoring DLL1 to the plasma membrane
- C-terminal intracellular domain: Short cytoplasmic tail involved in signal transduction
DLL1 undergoes several modifications that regulate its function:
- O-fucosylation: Glycosylation by POFUT1 is required for proper Notch binding
- N-glycosylation: Multiple N-linked glycosylation sites modulate protein stability
- Proteolytic cleavage: Shedding by ADAM proteases generates soluble DLL1 fragments with signaling activity
- Palmitoylation: Lipid modification facilitates membrane organization and signaling
The DLL1-Notch pathway is a fundamental mechanism for cell-cell communication in the nervous system:
flowchart TD
A["DLL1 on Signal-Sending Cell"] -->|"Juxtacrine binding"| B["NOTCH1/NOTCH2 on Signal-Receiving Cell"]
B -->|"Proteolytic cleavage"| C["S2 cleavage (ADAM)"]
C -->|"S3 cleavage"| D["S3 cleavage (gamma-secretase)"]
D --> E["NICD Release"]
E --> F["Nuclear Translocation"]
F --> G["RBPJkappa recruitment"]
G --> H["Transcriptional activation"]
H --> I["Target genes: Hes1, Hey1, Hes5, Myc, CyclinD1"]
I --> J["Neural stem cell maintenance"]
I --> K["Inhibition of differentiation"]
I --> L["Synaptic plasticity genes"]
M["Neural stem cell niche"] --> A
A --> N["Lateral inhibition"]
N --> O["Neuronal vs glial fate choice"]
style A fill:#e1f5fe,stroke:#333
style B fill:#e1f5fe,stroke:#333
style I fill:#c8e6c9,stroke:#333
¶ Neural Stem Cell Maintenance
In the adult brain, DLL1-Notch signaling is the primary mechanism maintaining neural stem cell identity:
- Lateral inhibition: DLL1-expressing neural progenitors activate Notch in neighboring cells, preventing their differentiation and maintaining the stem cell pool
- Self-renewal signaling: Constitutive Notch activation promotes proliferation of stem cells without premature differentiation
- Niche maintenance: DLL1 from niche cells (ependymal cells, astrocytes) provides essential Notch activation to stem cells
Adult neurogenesis in the hippocampus and SVZ is regulated by DLL1-Notch signaling:
- Type 1 → Type 2 transition: DLL1-Notch signaling inhibits the transition from active stem cells to transit-amplifying cells
- Dendrite development: Notch activation regulates dendritic morphology of newborn neurons
- Synapse formation: DLL1 at presynaptic terminals modulates postsynaptic Notch receptors during synapse formation
- Integration: Proper Notch signaling is required for the functional integration of new neurons into hippocampal circuits
DLL1 at synapses regulates activity-dependent synaptic modification:
- Hippocampal LTP: DLL1-Notch signaling is required for long-term potentiation in CA1 neurons
- Dendritic spine morphology: DLL1 modulates spine density and shape through Notch-dependent gene expression
- Learning and memory: Impaired Notch signaling disrupts hippocampus-dependent spatial memory
- Molecular pathways: DLL1-Notch activates CREB and regulates PSD-95, Synapsin, and NMDA receptor subunit expression
DLL1-Notch signaling is profoundly dysregulated in AD through multiple mechanisms:
- Amyloid-beta inhibition: Aβ directly downregulates DLL1 expression in neural stem cells and neurons, impairing Notch signaling
- Neurogenesis impairment: Aβ-mediated DLL1-Notch disruption reduces hippocampal neurogenesis, which is critical for memory formation
- Synaptic dysfunction: DLL1-Notch signaling regulates synaptic proteins; disruption contributes to synapse loss in AD
- Microglial modulation: Notch signaling in microglia promotes inflammatory states; DLL1 from neurons may modulate microglial activation
- APP processing crosstalk: Notch and APP share processing enzymes (ADAM10, gamma-secretase), creating bidirectional regulation
| AD Feature |
DLL1-Notch Role |
Evidence |
| Amyloid pathology |
Aβ inhibits DLL1 |
|
| Neurogenesis decline |
DLL1-Notch required |
|
| Synapse loss |
Regulates synaptic proteins |
|
| Cognitive decline |
Required for memory |
|
DLL1 contributes to PD pathophysiology through several pathways:
- Dopaminergic neuron survival: Notch signaling provides trophic support to substantia nigra dopaminergic neurons
- Neuroinflammation: DLL1-Notch in microglia and astrocytes modulates inflammatory responses that drive PD progression
- Protein aggregation crosstalk: Alpha-synuclein and Notch pathway interactions have been identified in PD models
- Mitochondrial dysfunction: Notch signaling influences mitochondrial quality control pathways relevant to PD
- Neurorestoration potential: Enhancing DLL1-Notch signaling may promote compensatory neurogenesis in PD
DLL1 mutations and dysregulation contribute to developmental brain disorders:
- Neurodevelopmental disorders: Altered Notch signaling contributes to autism spectrum disorders, intellectual disability, and schizophrenia
- Brain malformation: DLL1 mutations can cause cortical patterning defects
- Synaptic development: DLL1-Notch at the synapse regulates excitatory/inhibitory balance
Like many growth/survival pathways, DLL1-Notch has context-dependent roles in cancer:
- Tumor suppressor in some tissues: DLL1 is frequently silenced in breast, lung, and colorectal cancers
- Oncogenic in others: In certain contexts, DLL1-Notch promotes cancer stem cell maintenance
- Therapeutic targeting: DLL1-Notch pathway modulators are in cancer clinical trials
Approaches to therapeutically modulate DLL1-Notch signaling in neurodegeneration:
| Strategy |
Approach |
Status |
| DLL1 agonists |
Soluble DLL1-Fc fusion proteins |
Preclinical |
| Notch agonists |
Small molecule Notch activators |
Research |
| ADAM10 inhibitors |
Increase DLL1-Notch by reducing receptor cleavage |
Investigational |
| Gamma-secretase inhibitors |
Complex (ICV delivery, risk of side effects) |
Clinical (cancer) |
| Stem cell therapy |
DLL1-expressing neural stem cells |
Investigational |
| Gene therapy |
AAV-DLL1 delivery to hippocampus |
Preclinical |
- Complexity of Notch signaling: Notch has context-dependent pro-survival and pro-differentiation effects, requiring careful targeting
- Blood-brain barrier: DLL1-Fc fusion proteins may require intrathecal or intraventricular delivery
- Developmental toxicity: Notch modulators risk affecting normal brain development
- Combination approaches: DLL1-Notch enhancement may synergize with anti-amyloid therapies
DLL1 expression and Notch pathway activity may serve as:
- Neurogenesis marker: DLL1 levels in CSF or blood may reflect hippocampal neurogenesis rate
- AD progression marker: DLL1 expression inversely correlates with amyloid burden and cognitive decline
- Treatment response indicator: DLL1-Notch activity may predict response to neurogenesis-enhancing therapies
- Embryonic lethality: Dll1 null mice die around E13.5 with severe neural tube defects
- Conditional knockouts: Neuron-specific Dll1 deletion reveals role in synaptic plasticity
- Conditional knockout phenotypes: Impaired LTP, reduced dendritic spines, spatial memory deficits
- Viable: Dll1+/- mice survive with subtle phenotypes
- Increased neurogenesis: Paradoxically, reduced Notch signaling can release stem cells to differentiate
- Behavioral deficits: Learning and memory impairments
- Neuronal DLL1 OE: Enhanced neurogenesis and improved spatial memory
- Overexpression in AD models: Partial rescue of Aβ-induced neurogenesis deficits
¶ Signaling Pathways and Interactions
Key DLL1-Notch pathway interactions:
- Notch receptors: NOTCH1 (primary), NOTCH2, NOTCH3 (redundant roles in neural cells)
- RBPJkappa (CBF1): Transcription factor recruited by NICD to Notch target gene promoters
- Mastermind-like (MAML): Co-activator recruited with RBPJkappa
- HDAC complexes: Repressed by Notch signaling (negative regulation)
- NUMB: Endocytic adaptor that degrades Notch, creating asymmetry in divisions
Notch activation by DLL1 regulates expression of:
- Transcription factors: Hes1, Hes5, Hey1 (repressors of differentiation genes)
- Cell cycle regulators: Myc, CyclinD1 (promote stem cell proliferation)
- Synaptic proteins: PSD-95, Synapsin, NR2A, NR2B subunits
- Anti-apoptotic proteins: Bcl-2, Bcl-xL
- ** extracellular matrix**: Reelin, which modulates synaptic function
Key research areas for DLL1 include:
- Mechanism of Aβ inhibition: How does Aβ downregulate DLL1 and Notch signaling?
- Therapeutic delivery: Developing DLL1 agonists that cross the blood-brain barrier
- Cell-specific targeting: Identifying neurons vs. stem cells where DLL1 modulation would be most beneficial
- Combination therapies: DLL1-Notch enhancement with anti-amyloid or anti-tau approaches
- Neurogenesis enhancement: Using DLL1 modulation to boost hippocampal neurogenesis in AD
- Biomarker development: DLL1 as a marker of neurogenic capacity in AD patients
- Does DLL1 expression predict response to anti-amyloid immunotherapies?
- Can DLL1-Notch modulation protect against tau pathology as well as amyloid?
- What is the role of astrocyte-derived DLL1 vs. neuron-derived DLL1 in disease?
- Are DLL1-Notch effects on neuroinflammation disease-stage dependent?
DLL1 encodes the principal Notch ligand in the adult brain, critical for neural stem cell maintenance, adult neurogenesis, and synaptic plasticity. In Alzheimer's disease, amyloid-beta disrupts DLL1-Notch signaling, contributing to impaired neurogenesis and synaptic dysfunction. In Parkinson's disease, DLL1-Notch supports dopaminergic neuron survival and modulates neuroinflammation. Therapeutic targeting of DLL1-Notch signaling represents a regenerative approach to neurodegenerative disease, though careful consideration of pathway complexity and delivery challenges is needed.